Interest in NAD infusion UK services often starts with a straightforward question: can an intravenous treatment help with persistent tiredness, recovery or healthy ageing? The more useful question is whether the proposed treatment is clinically appropriate, supplied and administered safely, and described honestly. NAD+ therapy should be approached as a medical intervention requiring proper assessment and governance, not as a guaranteed route to improved energy or wellbeing.
What NAD+ infusion therapy involves
NAD+ is short for nicotinamide adenine dinucleotide, a coenzyme found naturally in all living cells. It has a central role in processes involved in energy metabolism, cellular signalling and the function of certain enzymes. The body can make NAD+ from dietary nutrients, including forms of vitamin B3.
An NAD+ infusion administers a prepared NAD+ solution into a vein, usually over a controlled period. The exact dose, dilution and infusion rate may vary between services. This variation matters: treatment protocols should not be treated as interchangeable, and a dose or rate suitable for one person may not be suitable for another.
The fact that NAD+ has recognised biological functions does not, on its own, establish that intravenous NAD+ will treat a particular symptom or health condition. This distinction is essential when assessing the information provided by a clinic.
NAD infusion UK evidence: what is known and uncertain
Research into NAD biology is active and scientifically interesting. However, evidence about NAD+ within cells, or about oral NAD-related compounds, cannot automatically be applied to intravenous NAD+ therapy. Route of administration, formulation, dose, study population and measured outcomes all affect what a study can tell us.
At present, the clinical evidence base does not establish NAD+ infusions as a proven treatment for fatigue, burnout, cognitive symptoms, ageing or general wellness. People may report subjective changes after an infusion, but individual experience cannot determine whether a treatment is effective, who is most likely to benefit, or whether changes were caused by the infusion rather than rest, hydration, expectation or other factors.
A responsible provider should be comfortable explaining these limitations. They should separate established facts about NAD+ physiology from claims about the outcomes of an IV treatment. Language such as “supports” or “boosts” can sound reassuring while remaining vague, so patients should ask what outcome is being proposed and what evidence supports it.
For clinicians and operators, this means promotional material, consultation discussions and consent documentation should avoid implying that NAD+ can diagnose, prevent or cure illness. Where a patient has persistent fatigue, unexplained weight change, breathlessness, low mood, sleep disturbance or other ongoing symptoms, an appropriate medical assessment should take priority over an infusion programme.
Assessment before an infusion
A high-quality service begins before the cannula is inserted. A clinician should take a relevant medical history, review medicines and supplements, ask about allergies and previous reactions, and consider the reason the person is seeking treatment. They should also identify whether symptoms require investigation by a GP, specialist or urgent care service instead.
Eligibility is not a box-ticking exercise. Particular care is needed where a person is pregnant or breastfeeding, has significant medical conditions, is receiving treatment for an ongoing illness, or has a history that may affect intravenous access or treatment safety. The appropriate course may be to defer treatment, request further medical information or advise another route of care.
Informed consent should be a genuine conversation. Before proceeding, a patient should understand the intended purpose of the infusion, the uncertainty around expected benefits, the practical process, likely side effects, material risks, alternatives and the option to decline. They should have time to ask questions without pressure to purchase a course of treatments.
Delivery standards matter as much as the ingredient
Any IV therapy carries risks because it involves venous access and administration of a substance directly into the bloodstream. Risks can include pain or bruising at the site, inflammation of the vein, infiltration or extravasation, infection and allergic or other adverse reactions. The risk profile also depends on the product used and the individual receiving it.
Some people receiving NAD+ infusions report symptoms such as nausea, abdominal discomfort, headache, flushing or chest discomfort, particularly if an infusion is delivered too quickly. This is one reason infusion rate, observation and a clear response plan matter. Symptoms during treatment should not simply be dismissed as something to endure.
A well-governed service should use appropriately trained practitioners, a suitable clinical environment, documented infection-prevention procedures and reliable systems for patient identification, record keeping and escalation. There should be a clear protocol for recognising and managing deterioration or an adverse reaction, including access to emergency equipment and staff trained to use it.
Product sourcing and medicines governance also deserve scrutiny. The clinic should be able to explain how its products are obtained, stored, prescribed where required and checked before administration. In the UK, professional accountability sits with the practitioners involved, and services must operate within the relevant regulatory, prescribing and medicines-management requirements. Registration with a professional regulator does not remove the need for sound clinical systems.
Questions to ask an NAD+ provider
Before booking, patients can use a short set of practical questions to assess whether a provider is communicating responsibly:
- Who will assess me, prescribe where appropriate and administer the infusion, and what professional registration do they hold?
- What is the proposed reason for this treatment in my case, and what evidence supports that use?
- What are the known risks, possible side effects and signs that mean the infusion should be slowed, stopped or escalated?
- How are the product, dose, infusion rate and treatment duration selected and documented?
- What emergency procedures, aftercare arrangements and adverse-event reporting processes are in place?
Clear answers do not guarantee a particular outcome, but reluctance to discuss limitations, safety procedures or professional responsibility should be a concern. Equally, claims of dramatic results, universal suitability or risk-free treatment are not consistent with responsible clinical communication.
When another route may be more appropriate
NAD+ therapy is not a substitute for investigating the causes of poor health. Fatigue and reduced concentration, for example, may relate to sleep, stress, nutrition, anaemia, thyroid disease, infection, medication effects, menopause, mental health or other conditions. The appropriate next step depends on the pattern, duration and severity of symptoms.
For someone who is otherwise well and considering an infusion as part of a broader wellbeing plan, the decision should still be proportionate. It may be reasonable to decide that the uncertain benefit does not justify the cost, inconvenience or IV-related risks. Others may choose to proceed after a suitable assessment, provided they understand that the treatment is not a replacement for preventative healthcare, balanced nutrition, adequate sleep or medical review when symptoms persist.
The safest starting point is a provider who treats your questions as part of care, not as an obstacle to booking. Careful assessment, transparent evidence discussions and accountable clinical practice provide a sounder basis for any decision about NAD+ therapy.